New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
09:26 EDTNAVBNavidea price target lowered to $3 from $5 at JMP Securities
JMP Securities cut its price target on Navidea after the company announced that it plans to wind down its development of drug candidates for Alzheimerís and Parkinsonís diseases and focus on its launch of Lymphoseek. The firm keeps an Outperform rating.
News For NAVB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
07:34 EDTNAVBNavidea reiterates FY15 Lymphoseek product revenue view $10M-$12M
Subscribe for More Information
07:34 EDTNAVBNavidea reports Q2 EPS (6c), two estimates (4c)
Subscribe for More Information
July 29, 2015
07:32 EDTNAVBNavidea wins $1.7M fast track NIH SBIR grant for evaluation of RA treatment
Subscribe for More Information
July 28, 2015
07:35 EDTNAVBNavidea, MGH to evaluate Manocept for detection of cardiovascular disease
Subscribe for More Information
July 23, 2015
08:50 EDTNAVBNavidea announces peer-reviewed publication of data on Lymphoseek
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use